FEG
IBB icon

Financial Enhancement Group’s iShares Biotechnology ETF IBB Stock Holding History

Financial Enhancement Group’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,972
Closed -$2.44M – 324
2021
Q4 		$2.44M Buy
+15,972
New +$2.47M 0.43% 42

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Financial Enhancement Group's IBB Position: Q1 2022 in Review

Financial Enhancement Group sold out of iShares Biotechnology ETF (IBB) in Q1 2022, closing a stake of 15,972 shares — an estimated $2.44M sold.

Financial Enhancement Group first reported a position in IBB in Q4 2021 and held it in 1 quarter. The position peaked at $2.44M in Q4 2021. 897 funds tracked by Wall St. Rank hold IBB as of Q1 2022.

  • Financial Enhancement Group reported no remaining iShares Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
  • Financial Enhancement Group sold 15,972 iShares Biotechnology ETF shares in Q1 2022, an estimated $2.44M.
  • Financial Enhancement Group first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 1 quarter.
  • Financial Enhancement Group's iShares Biotechnology ETF position peaked at $2.44M in Q4 2021.
  • 897 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2022.

Based on Financial Enhancement Group's 13F filing for Q1 2022, filed 18 May 2022.